Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Growth hormone (GH) secretagogues and related peptides are among the most studied compounds in muscle biology. They work by elevating GH and IGF-1 levels — two hormones central to muscle protein synthesis, satellite cell activation, and recovery. This guide covers eight of the most researched peptides and compounds used in muscle growth contexts, including their mechanisms, typical research doses, clinical evidence, and key considerations. No hype, no testimonials — just what the research says.
| Peptide | Mechanism | Research Dose | GH Release Type | Route |
|---|---|---|---|---|
| CJC-1295 | GHRH analog | 100–300 mcg | Sustained pulsatile | SubQ |
| Ipamorelin | Ghrelin mimetic (GHRP) | 200–300 mcg | Acute pulse | SubQ |
| MK-677 | Non-peptide GH secretagogue | 10–25 mg | Sustained (24h half-life) | Oral |
| Sermorelin | GHRH analog (GRF 1-29) | 200–500 mcg | Natural pulsatile | SubQ |
| GHRP-2 | Ghrelin mimetic (GHRP) | 100–300 mcg | Potent acute pulse | SubQ / IV |
| GHRP-6 | Ghrelin mimetic (GHRP) | 100–300 mcg | Strong acute pulse | SubQ |
| IGF-1 LR3 | Direct IGF-1 receptor agonist | 20–80 mcg | N/A (bypasses GH axis) | SubQ / IM |
| Tesamorelin | GHRH analog (FDA-approved) | 2 mg | Sustained pulsatile | SubQ |
GHRH Analog · SubQ · 100–300 mcg, 2–3 times daily
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates sustained growth hormone secretion. The no-DAC (Drug Affinity Complex) version — also called Modified GRF 1-29 — provides pulsatile GH release that more closely mimics natural physiology.
Mechanism: CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and secretion of growth hormone. The modified amino acid sequence provides resistance to enzymatic degradation, extending its biological half-life.
Key Research:Clinical trials have shown CJC-1295 increases GH and IGF-1 levels by 200–1000% without significantly altering other pituitary hormones. It is commonly studied in combination with GHRPs like Ipamorelin for synergistic effects.
Considerations: Side effects reported in studies include flushing, headache, dizziness, injection site reactions, and water retention. Contraindicated in active cancer, pregnancy, and pituitary disorders. Best administered on an empty stomach. The no-DAC version requires more frequent dosing but provides more physiological GH pulsatility.
Ghrelin Mimetic (GHRP) · SubQ · 200–300 mcg, 2–3 times daily
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is considered one of the mildest GHRPs with fewer side effects than alternatives like GHRP-6.
Mechanism: Ipamorelin mimics ghrelin and binds to the growth hormone secretagogue receptor (GHS-R) in the pituitary gland. Unlike other GHRPs, it does not significantly increase cortisol or prolactin levels, making it more selective in its growth hormone release.
Key Research: Clinical studies have demonstrated dose-dependent GH release. It has been studied in post-surgical recovery and bone health contexts. It is frequently combined with CJC-1295 for synergistic GH elevation.
Considerations: Side effects include headache, water retention, tingling or numbness in extremities, and increased hunger. Often stacked with CJC-1295 (no DAC) for enhanced efficacy. Best administered on an empty stomach, 30 minutes before or 2 hours after eating.
Non-Peptide GH Secretagogue · Oral · 10–25 mg, once daily
MK-677 (ibutamoren) is an orally active, non-peptide growth hormone secretagogue that mimics ghrelin’s action. Despite not being a peptide, it is commonly tracked alongside GH-releasing peptides due to its similar mechanism and use case. It elevates GH and IGF-1 levels without affecting cortisol.
Mechanism: MK-677 activates the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, stimulating GH release. Unlike GHRPs, it is orally bioavailable with a long half-life of approximately 24 hours. It increases GH pulsatility and elevates IGF-1 levels persistently.
Key Research: Multiple clinical trials in elderly and GH-deficient populations demonstrate sustained increases in GH and IGF-1, improvements in body composition, increased bone density, and improved sleep quality. A 2-year trial showed sustained IGF-1 elevation without tachyphylaxis. Not FDA-approved despite extensive human data.
Considerations: Common side effects include increased appetite, water retention and bloating, drowsiness, elevated fasting glucose, and joint stiffness. Typically taken at night due to GH-release timing and potential drowsiness. Long-term use may affect fasting glucose. Contraindicated in diabetes, active cancer, and congestive heart failure.
GHRH Analog (GRF 1-29) · SubQ · 200–500 mcg, once daily at bedtime
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH. It was previously FDA-approved (under the brand name Geref) for diagnosing and treating pediatric GH deficiency and is now widely used in anti-aging medicine.
Mechanism: Sermorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the natural production and pulsatile release of growth hormone. Unlike exogenous HGH, it preserves the hypothalamic-pituitary feedback loop and does not suppress endogenous GH production.
Key Research: Previously FDA-approved for pediatric GH deficiency before being discontinued for commercial reasons. Clinical data supports improved body composition, sleep quality, and skin elasticity in adults. It is one of the most well-characterized GH secretagogues in the literature.
Considerations: Administered before bed to amplify the natural nocturnal GH pulse. Fasting for at least 2 hours before injection improves efficacy. Effects may take 3–6 months to fully manifest. Side effects include injection site pain, flushing, headache, and dizziness.
Ghrelin Mimetic (GHRP) · SubQ / IV · 100–300 mcg, 2–3 times daily
GHRP-2 is a synthetic hexapeptide growth hormone secretagogue considered one of the most potent GHRPs available. It is approved in Japan as a diagnostic agent (pralmorelin) for GH deficiency.
Mechanism: GHRP-2 binds to the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells, stimulating growth hormone release. It also suppresses somatostatin, the inhibitory signal for GH release. Unlike GHRP-6, it has minimal impact on cortisol and prolactin at therapeutic doses but does increase appetite modestly through ghrelin-pathway activation.
Key Research: Clinical studies confirm potent, dose-dependent GH release in healthy subjects and GH-deficient patients. It has been studied for cachexia and age-related GH decline.
Considerations: Best administered on an empty stomach. Often combined with a GHRH analog (CJC-1295 or Sermorelin) for synergistic GH release. Side effects include increased appetite, water retention, tingling in extremities, mild cortisol elevation at high doses, and drowsiness.
Ghrelin Mimetic (GHRP) · SubQ · 100–300 mcg, 2–3 times daily
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue known for its strong GH-releasing effects and pronounced appetite stimulation. It was one of the first GHRPs developed and has been extensively studied since the 1980s.
Mechanism: GHRP-6 activates the ghrelin receptor (GHS-R1a) on pituitary cells, triggering robust growth hormone release. It strongly stimulates appetite via ghrelin pathway activation in the hypothalamus. It also increases cortisol and prolactin at higher doses, distinguishing it from more selective alternatives like Ipamorelin.
Key Research: Clinical trials confirm potent GH release and appetite stimulation. It has also been studied for cardioprotection, wound healing, and age-related GH decline.
Considerations:Strong hunger response occurs 15–20 minutes post-injection. Due to significant appetite stimulation, it may be preferred in underweight or cachectic contexts but may be less suitable for obesity management. Side effects include intense hunger, water retention, cortisol elevation, and elevated prolactin levels.
Direct IGF-1 Receptor Agonist · SubQ / IM · 20–80 mcg, once daily
IGF-1 LR3 is a modified form of insulin-like growth factor-1 with an extended half-life due to a 13-amino acid N-terminal extension and an arginine substitution at position 3. It is studied for its potent anabolic effects on skeletal muscle, including hyperplasia (new muscle fiber formation).
Mechanism:IGF-1 LR3 binds to IGF-1 receptors on muscle cells with reduced affinity for IGF binding proteins, resulting in higher circulating bioactive IGF-1. It activates the PI3K/Akt/mTOR pathway, promoting muscle protein synthesis, satellite cell activation, and inhibition of protein degradation. Its reduced IGFBP binding extends its biological half-life to 20–30 hours.
Key Research: Preclinical studies demonstrate significant muscle hypertrophy and hyperplasia, improved nitrogen retention, and enhanced recovery from muscle damage. It is widely studied in muscle biology and cachexia research. Banned by WADA and classified as a prohibited growth factor.
Considerations:IM injection into the target muscle is common for localized effects. Typical research cycles run 4–6 weeks. Must be careful with dosing due to hypoglycemia risk. Side effects include hypoglycemia, joint pain, jaw growth and extremity swelling with prolonged use, and gut distension at high doses.
GHRH Analog (FDA-Approved) · SubQ · 2 mg, once daily
Tesamorelin is an FDA-approved synthetic analog of GHRH used to reduce excess abdominal fat in HIV-associated lipodystrophy. It is the only GHRH analog with current FDA approval and is increasingly used off-label in anti-aging and metabolic health contexts.
Mechanism: Tesamorelin binds to GHRH receptors on the anterior pituitary, stimulating the synthesis and release of endogenous growth hormone. The trans-3-hexenoic acid modification enhances stability and receptor binding affinity compared to native GHRH.
Key Research: FDA-approved in 2010 for HIV-associated lipodystrophy based on Phase 3 trials demonstrating a 15% reduction in visceral adipose tissue. Studies also show improvements in trunk fat, lipid profiles, and IGF-1 levels. Cognitive benefits have been observed in APOE4-positive patients at risk for Alzheimer’s disease.
Considerations: FDA-approved dose is 2 mg once daily via subcutaneous injection in the abdomen. Should be administered on an empty stomach. Effects reverse upon discontinuation. Side effects include injection site reactions, joint pain, peripheral edema, and elevated IGF-1 levels.
Growth hormone secretagogues fall into three main categories, each working through a distinct mechanism to elevate GH levels. Understanding these categories is key to interpreting the research on muscle growth peptides.
GHRH Analogs
Examples: CJC-1295, Sermorelin, Tesamorelin
These bind to GHRH receptors on pituitary somatotroph cells and stimulate the production of new growth hormone. They amplify the natural GH pulse signal. Think of them as “turning up the volume” on the body’s existing GH production pathway. They preserve the hypothalamic-pituitary feedback loop.
Ghrelin Mimetics (GHRPs)
Examples: Ipamorelin, GHRP-2, GHRP-6, MK-677
These activate the ghrelin receptor (GHS-R1a), triggering the release of stored growth hormone from the pituitary and suppressing somatostatin (the GH-inhibitory signal). They work through a different pathway than GHRH analogs, which is why combining a GHRH analog with a GHRP produces synergistic — not just additive — GH elevation.
Direct Growth Factors
Examples: IGF-1 LR3
These bypass the GH axis entirely and act directly on muscle tissue via the IGF-1 receptor. IGF-1 LR3 activates the PI3K/Akt/mTOR pathway in muscle cells, directly stimulating protein synthesis and satellite cell activation. This makes it distinct from secretagogues, which work upstream by elevating GH.
Research commonly studies GHRH analogs and GHRPs together. For example, CJC-1295 + Ipamorelin is one of the most widely referenced combinations. The GHRH analog increases GH production while the GHRP triggers its release and suppresses the inhibitory somatostatin signal, creating a synergistic effect.
The most studied peptides for muscle growth work by increasing growth hormone (GH) and IGF-1 levels. CJC-1295 and Ipamorelin are commonly researched together as a GHRH/GHRP stack. MK-677 (ibutamoren) is an orally active GH secretagogue with extensive clinical trial data. IGF-1 LR3 acts directly on muscle tissue via the IGF-1 receptor. The best choice depends on the specific research context and goals.
GH peptides stimulate the pituitary gland to release growth hormone, which in turn increases IGF-1 production in the liver. IGF-1 activates the PI3K/Akt/mTOR pathway in muscle cells, promoting protein synthesis, satellite cell activation, and inhibition of protein degradation. This creates an anabolic environment conducive to muscle hypertrophy.
GHRH analogs (like CJC-1295 and Sermorelin) stimulate GH production by binding to GHRH receptors on the pituitary. GHRPs (like Ipamorelin, GHRP-2, and GHRP-6) work through the ghrelin receptor (GHS-R1a) to trigger GH release and suppress somatostatin. Using both together produces synergistic GH elevation greater than either alone.
MK-677 (ibutamoren) is not technically a peptide. It is a non-peptide, orally active growth hormone secretagogue that mimics ghrelin and activates the same GHS-R1a receptor as GHRPs. It is commonly discussed alongside GH peptides due to its similar mechanism and use case.
Research commonly studies GHRH analogs combined with GHRPs for synergistic effects. For example, CJC-1295 (a GHRH analog) is frequently combined with Ipamorelin (a GHRP). The GHRH analog stimulates GH production while the GHRP triggers its release and suppresses somatostatin, resulting in greater GH elevation than either compound alone.
GH and IGF-1 elevations can be measured within days of starting a GH secretagogue protocol. However, research suggests that body composition changes such as increased lean mass and reduced fat typically require 8 to 16 weeks of consistent use to become measurable. Some peptides like Sermorelin may take 3 to 6 months for full effects to manifest.
Common side effects reported in studies include water retention, increased appetite, tingling or numbness in extremities, headache, and joint stiffness. These effects are generally dose-dependent and related to elevated GH and IGF-1 levels. Each peptide has a distinct side-effect profile; for example, GHRP-6 causes pronounced hunger while Ipamorelin is considered more selective with fewer side effects.
Regulatory status varies by peptide and jurisdiction. Tesamorelin is FDA-approved and requires a prescription. Sermorelin was previously FDA-approved. Many GH peptides like CJC-1295 and Ipamorelin are available through compounding pharmacies with a prescription. MK-677 and IGF-1 LR3 are classified as research compounds. Always consult a healthcare provider before using any peptide.
Calculate doses, compare prices across vendors, explore the growth hormone stack, or build a custom protocol.
This guide is for educational and informational purposes only. It is not medical advice. The information presented is based on published research and does not constitute a recommendation to use any peptide. Consult a licensed healthcare provider before using any peptide or growth hormone secretagogue.
Disclosed Labs